David Horn Solomon joined Bionor in January 2015. Dr. Solomon has extensive experience as a CEO in listed biotech companies, healthcare investing and pharmacology research. Prior to joining Bionor Dr. Solomon was CEO of Zealand Pharma A/S (Nasdaq CO: ZEAL) from 2008 until 2015. Dr. Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York where he received his doctorate in 1991. Dr. Solomon has served as a faculty member at Columbia University’s College of Physicians and Surgeons. From 2003 to 2006 he headed healthcare investing at Carrot Capital Healthcare Ventures in New York. Dr. Solomon has held leadership positions at several biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals, Critical Diagnostics and Vital Sensors. He is currently on the boards of Onxeo in Paris (NYSE-Euronext and NASDAQ OMX), TxCell in Nice, France (NYSE-Euronext) and privately held Promosome, in La Jolla, CA.

medicine , immunology, Pharmaceuticals , Critical Diagnostics ,pharmacology research